Organ Transplant Rejection Medication Market - By Drug Class (Calcineurin Inhibitor, Antibodies, Antiproliferative Agent), Transplant Type (Kidney, Liver, Heart), Distribution Channel (Hospital, Retail Pharmacies), Global Forecast, 2023-2032

Organ Transplant Rejection Medication Market Size

Organ Transplant Rejection Medication Market size in 2022 was valued at USD 5.5 billion and is expected to witness growth at CAGR of 3.2% and reach USD 7.5 billion by 2032. The factors driving the growth of global organ transplant rejection medication includes increasing organ transplant procedures due to chronic diseases and technological advancements in organ transplantation and tissue engineering.
 

Organ transplant rejection refers to the immune response of a recipient's body against a transplanted organ or tissue, considering it as foreign and attempting to destroy it. The organ transplant rejection medications also known as immunosuppressive medications or immunosuppressants, are drugs used to suppress this immune response and allow the transplanted organ to function properly within the recipient's body.
 

COVID-19 Impact

Due to the pandemic, many hospitals and healthcare facilities faced challenges and had to reallocate resources and prioritize COVID-19 patients. This resulted in the reduction of non-essential medical procedures, including transplant diagnostics and organ transplantation. The challenges in organ procurement, transportation, and availability, causing delays and cancellations of transplant surgeries were majorly experienced. The global supply chain disruptions had a significant impact on the availability of pharmaceutical ingredients, packaging materials, and finished products which had led to the shortages or delays in obtaining necessary medications. To prevent organ rejection, the transplant recipients require careful monitoring and management of immunosuppressive medications. The pandemic disrupted routine medical appointments, due to utilization and prioritization of medical facilities for treating covid-19 patients, leading to potential challenges in medication management and adherence.
 

Organ Transplant Rejection Medication Market Driving & Restraining Factors

The increasing organ transplant procedures due to chronic diseases and technological advancements in organ transplantation and tissue engineering are the major factors driving the growth of the global market. The increasing prevalence of end-stage organ diseases and improved patient outcomes have increased the demand of organ transplant procedures. Due to the increasing number of transplants the demand for rejection medications is also growing.
 

The restraining factors of the global market are high cost of organ transplantation procedures and low availability of organs for transplantation. The cost of organ transplantation procedures is high, and the lifelong use of immunosuppressive medications can result in significant financial burden on patients.
 

Organ Transplant Rejection Medication Market Analysis

Based on drug class, the organ transplant rejection medicine market is segmented into calcineurin inhibitors, antibodies, antiproliferative agents, mTOR inhibitor, and steroids. In 2022, the calcineurin inhibitors accounted for significant market share of 35.7% due to high prescription rate of the drugs Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine) which belongs to this class. They help in preventing acute rejection episodes that can lead to organ dysfunction and failure if left untreated. In addition to this, these inhibitors are suitable for long-term use and can be used for post-transplant maintenance therapy. They are available in various forms, including oral formulations and intravenous preparations allowing flexibility in administration.
 

Based on transplant type, the organ transplant rejection medicine market is classified into kidney, liver, heart, lung, pancreas, and other transplant types. The kidney segment is expected to grow at CAGR of 3.3% during the forecast period. Kidneys are highly immunogenic organs to which immune systems are more likely to recognize and respond to them as foreign. This can result in a stronger immune response and a higher risk of rejection. Additionally, the number of patients with kidney transplant are increasing globally. For, instance, United Network of Organ Sharing, on an average, 68 people received a new kidney each day in 2021. Kidney transplants are more cost-effective compared to dialysis and people with kidney failure gets an opportunity to live without extended period of dialysis.
 

Based on the distribution channel, the organ transplant rejection medicine market is segmented into hospital, retail, and online pharmacies. The hospital pharmacies segment held highest market share of 61.6%. Hospital pharmacies are commonly used for dispensing and managing organ transplant rejection medications. The hospital pharmacies offer easy and rapid access to such medications for the hospitalized patients. The retail pharmacies accounted for second highest market share due to the availability of various organ transplant rejection medications, whereas the online pharmacies segment is expected to grow at fastest growth rate due to convenience and accessibility of purchasing such medicines.
 

The North America organ transplant rejection medicine market was valued to be USD 2.4 billion in 2022. The well-developed healthcare systems, advanced healthcare infrastructure, increasing healthcare expenditure, increasing prevalence of chronic diseases, increasing research and development, and presence of key players operating are some of the factors boosting the growth of this market. During the forecast period, Asia Pacific organ transplant rejection market is expected to grow due to the increasing number of organ transplant, increasing prevalence of chronic diseases, increased research and development of novel immunosupppressants, and expansion of key players.
 

Organ Transplant Rejection Medication Market Share

The key players in the organ transplant rejection medicine market are

• Astellas Pharma Inc.
• Sanofi
• Bristol-Myers Squibb Company
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Accord Healthcare Ltd
• Viatris, Inc.
• Dr. Reddy's Laboratories Ltd
• Veloxis Pharmaceuticals A/S
• GlaxoSmithKline plc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
 

Organ Transplant Rejection Medication Industry News:

• In July 2021, US FDA approved Astellas Pharma’s supplemental new drug application (sNDA) for PROGRAF (tacrolimus) for the preventing the organ rejection in adult and pediatric with lung transplant. This product launch helped the company to enhance their product portfolio and their revenue.
   
• In February 2023, Sirolimus tablets of Zydus received US FDA approval for organ rejection in transplant recipients. This product approval will help the company to strengthen its product portfolio and boost the revenue of the company.
   

The organ transplant rejection medication market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market Size, By Drug Class

• Calcineurin inhibitors
• Antibodies
• Antiproliferative agents
• mTOR inhibitor
• Steroids

Market Size, By Transplant Type

• Kidney
• Liver
• Heart
• Lung
• Pancreas
• Other transplant types

Market Size, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa